In addition, high PD-L1 expression can increase AFP and TIL levels in patients, providing a new perspective for the regulation of the PD-L1/PD-1 pathway in HCC immunotherapy (Liu et al., 2019). The gene discussed is AFP; the disease is hepatocellular carcinoma.